Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art. 53 LR-JCARE Indicative Announcement on Acceptance of Application for Registration and Marketing Authorization of Semaglutide Injection

Time:2024-06-12

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate for Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation

Time:2024-06-12

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Annual General Meeting

Time:2024-06-07

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining Drug Registration Certificate

Time:2024-05-27

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Anuual General Meeting

Time:2024-05-17

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining The U.S. FDA Approval for The Company's Drug Cetrorelix Acetate for Injection

Time:2024-04-26

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Appointment of Senior Executive of the Company

Time:2024-04-25

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2024 Second Extraordinary General Meeting

Time:2024-04-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Phase III Clinical Trial of TG-1000 Capsules Meeting the Primary Endpoint

Time:2024-04-17

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2024 Second Extraordinary General Meeting

Time:2024-04-02

< 1...8910...16 >